Anti-KIF4A/KIF4 antibody [EPR5459]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(13 Publications )
Rabbit Recombinant Monoclonal KIF4A/KIF4 antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Mouse, Human samples. Cited in 13 publications.
View Alternative Names
KIF4, KIF4A, Chromosome-associated kinesin KIF4A, Chromokinesin-A
- Flow Cyt (Intra)
Unknown
Flow Cytometry (Intracellular) - Anti-KIF4A/KIF4 antibody [EPR5459] (AB124903)
Intracellular flow cytometric analysis of permeablized 293 cells using ab124903 at 1/10 dilution (red) or a rabbit IgG negative control (green).
- WB
Unknown
Western blot - Anti-KIF4A/KIF4 antibody [EPR5459] (AB124903)
All lanes:
Western blot - Anti-KIF4A/KIF4 antibody [EPR5459] (ab124903) at 1/1000 dilution
Lane 1:
Mouse thymus tissue lysate at 10 µg
Lane 2:
HeLa cell lysate at 10 µg
Lane 3:
293T (Human embryonic kidney epithelial cell) cell lysate at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 140 kDa
Observed band size: 170 kDa
false
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-KIF4A/KIF4 antibody [EPR5459] (AB124903)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Related conjugates and formulations (1)
-
Anti-KIF4A/KIF4 antibody [EPR5459] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (13)
Recent publications for all applications. Explore the full list and refine your search
Nature 609:183-190 PubMed35922507
2022
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 22:1339 PubMed34630693
2021
Applications
Unspecified application
Species
Unspecified reactive species
Medicine 100:e26130 PubMed34032761
2021
Applications
Unspecified application
Species
Unspecified reactive species
Journal of ovarian research 14:71 PubMed34034774
2021
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 24: PubMed34013367
2021
Applications
Unspecified application
Species
Unspecified reactive species
Bioscience reports 41: PubMed33398330
2021
Applications
Unspecified application
Species
Unspecified reactive species
Thoracic cancer 12:512-524 PubMed33350074
2020
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 11:508 PubMed32641713
2020
Applications
Unspecified application
Species
Unspecified reactive species
Clinical cancer research : an official journal of the American Association for Cancer Research 26:1516-1528 PubMed31796514
2019
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 10:402 PubMed31127080
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com